Insight Guru Inc.

11/16/2026 | Press release | Distributed by Public on 11/16/2026 17:48

Why Is Everyone Ignoring DaVita Stock’s High Cash Yield

For questions about this article or underlying research, email [email protected].

DaVita (DVA) produces free cash flow equal to 11.6% of its market value, against 4.2% for the median S&P 500 company. A cash yield that high usually marks one of two things: a business on sale, or one the market expects to shrink. So why does DaVita's share price give so little credit for that cash?

DaVita Owes More Than Its Shares Are Worth

DaVita's net debt, its borrowings and lease obligations minus its cash, stood at $12.8 billion at the end of September 2026, or 115% of its market value. Counted against the whole company, debt included, the cash yield is lower, and the share price appears to count that debt against the cash. Operating income covered DaVita's interest bill 3.6 times over the twelve months ended September 2026.

None of that changes who owns the cash. Each DaVita share is a claim on the free cash the company produces, paid out or not, just as it is a claim on its profit. Cash the company keeps is still the shareholders' money, and share prices tend to follow it once investors take notice, more so when that cash is rising.

Most of DaVita's revenue comes from dialysis: U.S. dialysis brought in $11.7 billion of the company's $13.6 billion of revenue in fiscal 2025. Capital spending took 30.8% of DaVita's cash from operations over the twelve months ended September 2026. Free cash flow has stayed positive in every twelve-month period measured from September 2023 to September 2026, and it was $1.29 billion in the latest, against $1.31 billion three years earlier.

DaVita's Dialysis Costs Are Outrunning Revenue Per Treatment

During the October 29 call, management said patient care cost per treatment in U.S. dialysis rose 2.4% in the third quarter of 2026 from a year earlier. Over the same period, it said revenue per treatment rose about 1.1%. Management said a lower commercial mix and lower phosphate binder reimbursement offset normal rate increases.

Management also said its IT investment in U.S. dialysis ran higher than forecast in 2026, and that technology spending has grown more than 20% a year for the last three or four years, though it expects that growth to slow. It still expects 2026 free cash flow of $1 billion to $1.25 billion, on its own measure. To lift volume, DaVita said it would begin a national rollout of its new expanded HD dialyzers the following week, and management expects higher volume growth from it to begin in the back half of 2028.

Yet the company as a whole is not shrinking. Revenue grew 6.4% over the twelve months ended September 2026, and operating margin over that period reached 15.2%, up from 14.6% a year earlier. Those figures look more like a business on sale than one in decline.

Will DaVita's Cash Grow, And Is Its Debt Covered?

Neither question is settled yet. DaVita's free cash flow has not grown in three years, and management said it is too early to give full guidance for 2027. Management expects higher volume growth in 2027 than in 2026, but also a headwind to revenue per treatment from commercial mix, with Affordable Care Act plans being the biggest part. On the debt, the open question is whether operating income keeps covering interest as comfortably as it has over the last twelve months.

DaVita is expected to report in February 2027. Its full-year free cash flow on management's own measure, set against the range it reaffirmed in October, is the number to watch.

Does This Mean You Should Act On DVA?

Betting on a single stock is always risky, whichever way you lean. The Trefis High Quality (HQ) Portfolio holds 30 quality companies in equal weight and has returned 105% since its September 2020 launch.

See The HQ Portfolio

Spot an error or want more like this? Tell us in 10 seconds.

Insight Guru Inc. published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 16, 2026 at 23:48 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]